{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:42:45Z","timestamp":1748367765671},"reference-count":262,"publisher":"Impact Journals, LLC","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.18632\/oncotarget.27709","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T15:01:08Z","timestamp":1598972468000},"page":"3315-3349","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin\u2019s lymphoma to many other types of solid cancers"],"prefix":"10.18632","volume":"11","author":[{"given":"Rod","family":"Balhorn","sequence":"first","affiliation":[{"name":"SHAL Technologies Inc., Livermore, CA 94550, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique Cosman","family":"Balhorn","sequence":"additional","affiliation":[{"name":"SHAL Technologies Inc., Livermore, CA 94550, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/blood.V83.7.1760.1760","article-title":"A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity","volume":"8","author":"Old","year":"1994","journal-title":"Blood"},{"key":"2","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"10","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"35","author":"Wahl","year":"2005","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: phase I\/II clinical trial results","volume":"1","author":"Eschenberg","year":"2004","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"9","author":"Cragg","year":"2010","journal-title":"Haematologica"},{"key":"6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Ho","year":"2008","journal-title":"Lancet Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"6","author":"Figgitt","year":"2003","journal-title":"Drugs"},{"key":"8","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"2","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/10428190310001598017","article-title":"Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia\u2013change of regimen needed?","volume":"4","author":"Knauf","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"3","author":"Bruggemann","year":"2014","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"27","author":"Parren","year":"2016","journal-title":"Immunol Rev"},{"key":"12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2217\/imt-2016-0146","article-title":"Neoepitopes as cancer immunotherapy targets: key challenges and opportunities","volume":"9","author":"Ebrahimi-Nik","year":"2017","journal-title":"Immunotherapy"},{"key":"13","doi-asserted-by":"publisher","first-page":"e93231","DOI":"10.1371\/journal.pone.0093231","article-title":"Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response","volume":"9","author":"Arredouani","year":"2014","journal-title":"PLoS One"},{"key":"14","first-page":"6230","article-title":"MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte","volume":"5","author":"Rosenberg","year":"1999","journal-title":"Cancer Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jprot.2018.01.004","article-title":"MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection","volume":"17","author":"Levin","year":"2018","journal-title":"J Proteomics"},{"key":"16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/intimm\/dxn063","article-title":"Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4","volume":"2","author":"Harrop","year":"2008","journal-title":"Int Immunol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1054\/bjoc.2001.2089","article-title":"Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope","volume":"8","author":"Papamichail","year":"2001","journal-title":"Br J Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-05-2470","article-title":"Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas","volume":"1","author":"Stenzl","year":"2006","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4172\/2155-9899.1000351","article-title":"Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design","volume":"6","author":"Haque","year":"2015","journal-title":"J Clin Cell Immunol"},{"key":"20","first-page":"5715","article-title":"CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7","volume":"16","author":"Maeurer","year":"1999","journal-title":"J Immunol"},{"key":"21","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.4049\/jimmunol.170.12.6363","article-title":"Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen","volume":"17","author":"Castelli","year":"2003","journal-title":"J Immunol"},{"key":"22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1084\/jem.189.5.757","article-title":"Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells","volume":"18","author":"Topalian","year":"1999","journal-title":"J Exp Med"},{"key":"23","first-page":"3260","article-title":"Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen","volume":"9","author":"Chen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/1471-2407-12-561","article-title":"Profound tumor-specific Th2 bias in patients with malignant glioma","volume":"1","author":"Anderson","year":"2012","journal-title":"BMC Cancer"},{"key":"25","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1073\/pnas.91.20.9461","article-title":"Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene","volume":"9","author":"Rosenberg","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"26","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1073\/pnas.061507398","article-title":"CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production","volume":"9","author":"Wang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/1535-7163.MCT-17-0354","article-title":"IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma","volume":"1","author":"Goldenberg","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"28","first-page":"17","article-title":"Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody","volume":"1","author":"Epstein","year":"1988","journal-title":"Antibody Immunoconjugates Radiopharm"},{"key":"29","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2706::AID-CNCR49>3.0.CO;2-D","article-title":"Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia","volume":"8","author":"DeNardo","year":"1997","journal-title":"Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/cbr.1998.13.239","article-title":"Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody","volume":"1","author":"Shen","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"key":"31","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin\u2019s lymphoma","volume":"1","author":"Lewis","year":"1998","journal-title":"J Clin Oncol"},{"key":"32","first-page":"1253","article-title":"Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies","volume":"3","author":"Kroger","year":"1997","journal-title":"Clin Cancer Res"},{"key":"33","first-page":"2014","article-title":"A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin\u2019s lymphoma","volume":"4","author":"DeNardo","year":"1999","journal-title":"J Nucl Med"},{"key":"34","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood-2006-04-017921","article-title":"Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab","volume":"10","author":"Goldenberg","year":"2006","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1182\/blood-2009-06-228288","article-title":"Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways","volume":"11","author":"Goldenberg","year":"2010","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood.V126.23.2740.2740","article-title":"Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a Phase I First-in-Man Study in hematologic malignancies","volume":"12","author":"Christian","year":"2015","journal-title":"Blood"},{"key":"37","first-page":"830","article-title":"Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential","volume":"4","author":"Taylor","year":"1987","journal-title":"Cancer Res"},{"key":"38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/00007890-198908000-00011","article-title":"The relevance of induced class II HLA antigens and macrophage infiltration in early renal allograft biopsies","volume":"4","author":"Cameron","year":"1989","journal-title":"Transplantation"},{"key":"39","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0161-5890(99)00083-8","article-title":"Critical Lym-1 binding residues on polymorphic HLA-DR molecules","volume":"3","author":"Meares","year":"1999","journal-title":"Mol Immunol"},{"key":"40","first-page":"2779","article-title":"Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin\u2019s lymphoma: a pilot study","volume":"1","author":"Meares","year":"1998","journal-title":"Anticancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/ejh.12396","article-title":"Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature","volume":"9","author":"Rieger","year":"2015","journal-title":"Eur J Haematol"},{"key":"42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nrl.2011.02.004","article-title":"Safety profile and practical considerations of monoclonal antibody treatment","volume":"2","author":"Casanova Estruch","year":"2013","journal-title":"Neurologia"},{"key":"43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"Advani","year":"2014","journal-title":"J Hematol Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood-2015-09-670802","article-title":"Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions","volume":"12","author":"Cartron","year":"2015","journal-title":"Blood"},{"key":"45","first-page":"1921","article-title":"The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A","volume":"6","author":"Riethmuller","year":"2000","journal-title":"Cancer Res"},{"key":"46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"George","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"47","first-page":"251","article-title":"A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies","volume":"4","author":"Denardo","year":"2004","journal-title":"Not four letter words. Q J Nucl Med Mol Imaging"},{"key":"48","doi-asserted-by":"publisher","first-page":"e26642","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy","volume":"6","author":"Pressey","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"49","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1172\/JCI119110","article-title":"Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a\/CD18 (LFA-1) on NK cells","volume":"9","author":"Compston","year":"1996","journal-title":"J Clin Invest"},{"key":"50","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"9","author":"Engert","year":"1999","journal-title":"Blood"},{"key":"51","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1089\/cbr.2008.0589","article-title":"Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging","volume":"2","author":"Balhorn","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"52","first-page":"511","article-title":"Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia","volume":"3","author":"Balhorn","year":"2009","journal-title":"Int J Oncol"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2020.1787418","article-title":"The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers","author":"Rebhun","year":"2020","journal-title":"J Drug Target"},{"key":"54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.vetimm.2010.05.014","article-title":"A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin\u2019s lymphoma also binds to canine B-cell lymphomas","volume":"13","author":"Rebhun","year":"2010","journal-title":"Vet Immunol Immunopathol"},{"key":"55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4049\/jimmunol.167.1.98","article-title":"Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter","volume":"16","author":"Alcaide-Loridan","year":"2001","journal-title":"J Immunol"},{"key":"56","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Frederick","year":"2016","journal-title":"Nat Commun"},{"key":"57","first-page":"1019","article-title":"Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma","volume":"4","author":"Ferrone","year":"1988","journal-title":"Cancer Res"},{"key":"58","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1167\/iovs.11-8901","article-title":"A comparison of HLA genotype with inflammation in uveal melanoma","volume":"5","author":"Jager","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"59","first-page":"4009","article-title":"HLA class II antigen expression in human papillomavirus-associated cervical cancer","volume":"5","author":"Stern","year":"1992","journal-title":"Cancer Res"},{"key":"60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ajcp\/101.1.5","article-title":"The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma","volume":"10","author":"Fleuren","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"61","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.1128\/JVI.74.14.6632-6636.2000","article-title":"Human papillomavirus type 33 E7 peptides presented by HLA-DR0402 to tumor-infiltrating T cells in cervical cancer","volume":"7","author":"Maeurer","year":"2000","journal-title":"J Virol"},{"key":"62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/ijc.21226","article-title":"Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance","volume":"11","author":"Maeurer","year":"2005","journal-title":"Int J Cancer"},{"key":"63","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.1158\/1078-0432.CCR-08-0479","article-title":"Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer","volume":"1","author":"Mok","year":"2008","journal-title":"Clin Cancer Res"},{"key":"64","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1002\/ijc.22266","article-title":"HLA-class II haplotype associations with ovarian cancer","volume":"11","author":"van der Ven","year":"2006","journal-title":"Int J Cancer"},{"key":"65","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/ijc.23624","article-title":"Genetic alterations of HLA-class II in ovarian cancer","volume":"12","author":"van der Ven","year":"2008","journal-title":"Int J Cancer"},{"key":"66","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4161\/cbt.3.10.1142","article-title":"Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers","volume":"3","author":"Morin","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"67","doi-asserted-by":"publisher","first-page":"E9942","DOI":"10.1073\/pnas.1707658114","article-title":"The immunopeptidomic landscape of ovarian carcinomas","volume":"11","author":"Braun","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10238-003-0013-0","article-title":"Prognostic significance of HLA-DR antigen in serous ovarian tumors","volume":"3","author":"Papadopoulos","year":"2003","journal-title":"Clin Exp Med"},{"key":"69","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/pros.2990190108","article-title":"Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade","volume":"1","author":"Castagnola","year":"1991","journal-title":"Prostate"},{"key":"70","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/cb6003788","article-title":"Selective tumor cell targeting using low-affinity, multivalent interactions","volume":"2","author":"Kiessling","year":"2007","journal-title":"ACS Chem Biol"},{"key":"71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1876401001003010001","article-title":"HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy","volume":"3","author":"Haque","year":"2010","journal-title":"Open Cancer Immunol J"},{"key":"72","first-page":"41","article-title":"Survival of the fittest or best adapted: HLA-dependent tumor development","volume":"1","author":"Kiessling","year":"2010","journal-title":"J Nucleic Acids Investig"},{"key":"73","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/sj.pcan.4501021","article-title":"HLA class II antigen presentation by prostate cancer cells","volume":"1","author":"Haque","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"74","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ijc.20860","article-title":"Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma","volume":"11","author":"Oka","year":"2005","journal-title":"Int J Cancer"},{"key":"75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/bjc.1988.84","article-title":"HLA expression in human hepatocellular carcinoma","volume":"5","author":"Desmet","year":"1988","journal-title":"Br J Cancer"},{"key":"76","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1172\/JCI113900","article-title":"Expression of class I and class II major histocompatibility antigens on human hepatocellular carcinoma","volume":"8","author":"Chang","year":"1989","journal-title":"J Clin Invest"},{"key":"77","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-2249.1994.tb06089.x","article-title":"HLA expression in hepatocellular carcinoma cell lines","volume":"9","author":"Reddy","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"78","first-page":"361","article-title":"Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma","volume":"15","author":"Bander","year":"1996","journal-title":"J Urol"},{"key":"79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0344-0338(98)80126-X","article-title":"Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma","volume":"19","author":"Dirnhofer","year":"1998","journal-title":"Pathol Res Pract"},{"key":"80","doi-asserted-by":"publisher","first-page":"250435","DOI":"10.1155\/2013\/250435","article-title":"Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer","volume":"201","author":"Soares","year":"2013","journal-title":"Int J Breast Cancer"},{"key":"81","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/jcp.53.4.286","article-title":"HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities","volume":"5","author":"Okon","year":"2000","journal-title":"J Clin Pathol"},{"key":"82","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00129039-200109000-00007","article-title":"Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases","volume":"9","author":"Hessner","year":"2001","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"83","doi-asserted-by":"publisher","first-page":"e87377","DOI":"10.1371\/journal.pone.0087377","article-title":"Activation of ERalpha signaling differentially modulates IFN-gamma induced HLA-class II expression in breast cancer cells","volume":"9","author":"Drover","year":"2014","journal-title":"PLoS One"},{"key":"84","doi-asserted-by":"publisher","first-page":"e0182786","DOI":"10.1371\/journal.pone.0182786","article-title":"Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling","volume":"1","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"85","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/bcr278","article-title":"Challenges to the development of antigen-specific breast cancer vaccines","volume":"3","author":"Jager","year":"2001","journal-title":"Breast Cancer Res"},{"key":"86","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00262-017-1983-1","article-title":"HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients","volume":"6","author":"O\u2019Sullivan","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"87","first-page":"458","article-title":"Pathogenesis of esophageal squamous cell carcinoma with lymphoid stroma","volume":"4","author":"Sugimachi","year":"2001","journal-title":"Hepatogastroenterology"},{"key":"88","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/1097-0142(19940715)74:2<586::AID-CNCR2820740209>3.0.CO;2-4","article-title":"Local immune response to tumor invasion in esophageal squamous cell carcinoma","volume":"7","author":"Sugimachi","year":"1994","journal-title":"The expression of human leukocyte antigen-DR and lymphocyte infiltration. Cancer"},{"key":"89","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4253\/wjge.v6.i8.385","article-title":"Lymphoepithelioma-like esophageal carcinoma with macroscopic reduction","volume":"6","author":"Matsubara","year":"2014","journal-title":"World J Gastrointest Endosc"},{"key":"90","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/archotol.1990.01870100075016","article-title":"HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck","volume":"11","author":"Zajdel","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"91","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ijc.2910470719","article-title":"HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites","volume":"6","author":"Ruiter","year":"1991","journal-title":"Int J Cancer Suppl"},{"key":"92","first-page":"24","article-title":"Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma","volume":"5","author":"Epstein","year":"2013","journal-title":"Head Neck Oncol"},{"key":"93","doi-asserted-by":"publisher","first-page":"721","DOI":"10.14670\/HH-15.721","article-title":"Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma","volume":"1","author":"Agnantis","year":"2000","journal-title":"Histol Histopathol"},{"key":"94","first-page":"207","article-title":"Immunohistochemical prognostic markers in bladder cancer","volume":"7","author":"Agnantis","year":"2002","journal-title":"J BUON"},{"key":"95","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/path.1711740307","article-title":"HLA-DR antigen expression and lymphocyte subsets in transitional cell carcinoma of the urinary bladder","volume":"17","author":"Agnantis","year":"1994","journal-title":"An immunohistological study on frozen sections. J Pathol"},{"key":"96","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1464-410X.1989.tb05187.x","article-title":"HLA-DR expression by high grade superficial bladder cancer treated with BCG","volume":"6","author":"Smyth","year":"1989","journal-title":"Br J Urol"},{"key":"97","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000011870","article-title":"Combined expression of HLA-DR antigen and proliferating cell nuclear antigen correlate with colorectal cancer prognosis","volume":"5","author":"Shimamoto","year":"1998","journal-title":"Oncology"},{"key":"98","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.bjc.6600507","article-title":"Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis","volume":"8","author":"Rognum","year":"2002","journal-title":"Br J Cancer"},{"key":"99","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/bjc.1996.112","article-title":"HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gammaand its association with tumour progression","volume":"7","author":"Isono","year":"1996","journal-title":"Br J Cancer"},{"key":"100","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1349-7006.2006.00137.x","article-title":"Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma","volume":"9","author":"Ochiai","year":"2006","journal-title":"Cancer Sci"},{"key":"101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1593\/neo.131568","article-title":"HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker","volume":"1","author":"Ferrone","year":"2014","journal-title":"Neoplasia"},{"key":"102","first-page":"2609","article-title":"Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of tumor-induced immunosuppression?","volume":"2","author":"Gorgoulis","year":"2001","journal-title":"Anticancer Res"},{"key":"103","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/BF02899573","article-title":"Expression of MHC class II antigens in human lung cancer cells","volume":"6","author":"Iijima","year":"1991","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"104","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ijc.30489","article-title":"The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration","volume":"14","author":"Ruiz-Cabello","year":"2017","journal-title":"Int J Cancer"},{"key":"105","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2370.1998.00116.x","article-title":"Differential expression of MHC class II genes in lung tumour cell lines","volume":"2","author":"Garrido","year":"1998","journal-title":"Eur J Immunogenet"},{"key":"106","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2249.2006.03289.x","article-title":"Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines","volume":"14","author":"Lemoine","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"107","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF01810678","article-title":"HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx","volume":"8","author":"Garrido","year":"1990","journal-title":"Clin Exp Metastasis"},{"key":"108","first-page":"297","article-title":"Quantitative analysis of HLA DR expression and lymphocytic infiltrate in laryngeal cancer including clinical and morphological correlations","volume":"14","author":"Wagrowska-Danilewicz","year":"1998","journal-title":"Gen Diagn Pathol"},{"key":"109","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1699-0463.1999.tb01569.x","article-title":"HLA-DR expression is a significant prognostic factor in laryngeal cancer","volume":"10","author":"Wagrowska-Danilewicz","year":"1999","journal-title":"A morphometric study. APMIS"},{"key":"110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000011837","article-title":"Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer","volume":"5","author":"Sonoda","year":"1998","journal-title":"Oncology"},{"key":"111","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/02841869409098403","article-title":"Expression of HLA-class II antigen in gastric carcinomas","volume":"3","author":"Kodama","year":"1994","journal-title":"Its relationship to histopathological grade, lymphocyte infiltration and five-year survival rate. Acta Oncol"},{"key":"112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s101200050057","article-title":"Expression of HLA-DR and urokinase-type plasminogen activator in stage IV gastric cancer","volume":"1","author":"Kodama","year":"1998","journal-title":"Gastric Cancer"},{"key":"113","first-page":"923","article-title":"Expression and function of class II antigens on gastric carcinoma cells and gastric epithelia: differential expression of DR, DQ, and DP antigens","volume":"7","author":"Kano","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41016-017-0090-7","article-title":"Expression of HLA-DR genes in gliomas: correlation with clinicopathological features and prognosis","volume":"3","author":"Jiang","year":"2017","journal-title":"Chinese Neurosurgical Journal"},{"key":"115","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5411\/wji.v3.i3.62","article-title":"Tumor antigen and MHC expression in glioma cells for immunotherapeutic interventions","volume":"3","author":"Linnebacher","year":"2013","journal-title":"World J Immunol"},{"key":"116","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/030089169107700206","article-title":"HLA-Dr expression by tumor cells compared with survival in high grade astrocytomas","volume":"7","author":"Coakham","year":"1991","journal-title":"Tumori"},{"key":"117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF03348579","article-title":"Expression of HLA ABC and DR antigens in thyroid neoplasia and correlation with mononuclear leukocyte infiltration","volume":"1","author":"Jones","year":"1990","journal-title":"J Endocrinol Invest"},{"key":"118","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ijc.23167","article-title":"Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer","volume":"12","author":"Shong","year":"2008","journal-title":"Int J Cancer"},{"key":"119","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jcem.83.1.4489","article-title":"Is human leukocyte antigen-DR and intercellular adhesion molecule-1 expression on human thyrocytes constitutive in papillary thyroid cancer? Comparative studies in human thyroid xenografts in severe combined immunodeficient and nude mice","volume":"8","author":"Volpe","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"120","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/thy.1998.8.361","article-title":"Regulation of HLA-DR and costimulatory B7 molecules in human thyroid carcinoma cells: differential binding of transcription factors to the HLA-DRalpha promoter","volume":"8","author":"Kraiem","year":"1998","journal-title":"Thyroid"},{"key":"121","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/0008-5472.CAN-06-3744","article-title":"IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3","volume":"6","author":"Gianni","year":"2007","journal-title":"Cancer Res"},{"key":"122","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1146\/annurev.iy.11.040193.003035","article-title":"The molecular cell biology of interferon-gamma and its receptor","volume":"1","author":"Schreiber","year":"1993","journal-title":"Annu Rev Immunol"},{"key":"123","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","article-title":"Regulation of interferon-gamma during innate and adaptive immune responses","volume":"9","author":"Wilson","year":"2007","journal-title":"Adv Immunol"},{"key":"124","first-page":"1492","article-title":"Recombinant interferon-gamma increases HLA-DR synthesis and expression","volume":"13","author":"Merigan","year":"1983","journal-title":"J Immunol"},{"key":"125","first-page":"1261","article-title":"HLA-DR synthesis induction and expression in HLA-DR-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta","volume":"7","author":"Seehafer","year":"1985","journal-title":"J Natl Cancer Inst"},{"key":"126","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1182\/blood.V90.5.1960","article-title":"Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells","volume":"9","author":"Holm","year":"1997","journal-title":"Blood"},{"key":"127","first-page":"3943","article-title":"Control of HLA-DR antigen expression by gamma-interferon: separate signal transduction mechanisms in malignant and nonmalignant human thyroid cells","volume":"5","author":"Kraiem","year":"1993","journal-title":"Cancer Res"},{"key":"128","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/jnci\/90.4.287","article-title":"Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas","volume":"9","author":"Fridman","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"129","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"13","author":"Lin","year":"2013","journal-title":"Int J Cancer"},{"key":"130","first-page":"580","article-title":"Adrenocortical cells of the zona reticularis normally express HLA-DR antigenic determinants","volume":"12","author":"Greenspan","year":"1987","journal-title":"Am J Pathol"},{"key":"131","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1210\/jcem.82.9.4194","article-title":"Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differentiation in the human adrenal cortex","volume":"8","author":"Scherbaum","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"132","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0014-4886(90)90054-V","article-title":"Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer\u2019s disease brain","volume":"11","author":"Rogers","year":"1990","journal-title":"Exp Neurol"},{"key":"133","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/mp.2017.246","article-title":"Markers of microglia in post-mortem brain samples from patients with Alzheimer\u2019s disease: a systematic review","volume":"2","author":"Bazinet","year":"2018","journal-title":"Mol Psychiatry"},{"key":"134","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0165-5728(89)90115-X","article-title":"Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease","volume":"2","author":"Selkoe","year":"1989","journal-title":"J Neuroimmunol"},{"key":"135","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1084\/jem.173.1.19","article-title":"A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis","volume":"17","author":"McFarland","year":"1991","journal-title":"J Exp Med"},{"key":"136","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0304-3940(87)90696-3","article-title":"Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR","volume":"7","author":"McGeer","year":"1987","journal-title":"Neurosci Lett"},{"key":"137","first-page":"535","article-title":"HLA class II molecules (HLA-DR, -DP, -DQ) on cells in the human CNS studiedand","volume":"8","author":"M\u00f8rk","year":"1994","journal-title":"Immunology"},{"key":"138","doi-asserted-by":"publisher","first-page":"548","DOI":"10.4049\/jimmunol.169.1.548","article-title":"High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes","volume":"16","author":"Melms","year":"2002","journal-title":"J Immunol"},{"key":"139","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1365-2249.2000.01164.x","article-title":"Expression of HLA-DR, costimulatory molecules B7-1, B7-2, intercellular adhesion molecule-1 (ICAM-1) and Fas ligand (FasL) on gastric epithelial cells in Helicobacter pylori gastritis; influence of H. pylori eradication","volume":"11","author":"Moutsopoulos","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"140","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/gut.27.2.153","article-title":"Expression of HLA-DR antigens on epithelium associated with lymphoid tissue in the human gastrointestinal tract","volume":"2","author":"Isaacson","year":"1986","journal-title":"Gut"},{"key":"141","first-page":"310","article-title":"Coexpression of aspartic proteinases and human leukocyte antigen-DR in human transplanted lung","volume":"14","author":"Solicia","year":"1994","journal-title":"Am J Pathol"},{"key":"142","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0039-6060(98)70096-0","article-title":"Major histocompatibility complex class II expression and parathyroid autoantibodies in primary hyperparathyroidism","volume":"12","author":"Klareskog","year":"1998","journal-title":"Surgery"},{"key":"143","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1464-410X.2003.04091.x","article-title":"Loss of CD38 correlates with simultaneous up-regulation of human leukocyte antigen-DR in benign prostatic glands, but not in fetal or androgen-ablated glands, and is strongly related to gland atrophy","volume":"9","author":"Marberger","year":"2003","journal-title":"BJU Int"},{"key":"144","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/00007890-198606000-00021","article-title":"Expression of class I and class II major histocompatibility antigens in normal and transplanted human heart","volume":"4","author":"Yacoub","year":"1986","journal-title":"Transplantation"},{"key":"145","first-page":"442","article-title":"Pulmonary eosinophils express HLA-DR in chronic eosinophilic pneumonia","volume":"9","author":"Lucey","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"146","first-page":"165","article-title":"The density of HLA-DR antigen expression on alveolar macrophages is increased in pulmonary sarcoidosis","volume":"6","author":"Poulter","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"147","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/00007890-199210000-00014","article-title":"Rejection in lung transplantation\u2013an immunohistochemical study of transbronchial biopsies","volume":"5","author":"Brousse","year":"1992","journal-title":"Transplantation"},{"key":"148","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1164\/ajrccm\/139.2.330","article-title":"The distribution of MHC class I and II antigens on bronchial epithelium","volume":"13","author":"Robin","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"149","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/BF02779357","article-title":"HLA-DR, -DP, and -DO) antigens on intestinal epithelia in ulcerative colitis, Crohn\u2019s disease, colorectal cancer and normal small intestine","volume":"2","author":"Class","year":"1990","journal-title":"Gastroenterol Jpn"},{"key":"150","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ajpath.2010.10.027","article-title":"Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis","volume":"17","author":"Justinich","year":"2011","journal-title":"Am J Pathol"},{"key":"151","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/00000478-199908000-00016","article-title":"Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn\u2019s disease","volume":"2","author":"Stolte","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"152","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/00007890-199005000-00030","article-title":"HLA-class II antigen expression in human heart-lung allografts","volume":"4","author":"Griffith","year":"1990","journal-title":"Transplantation"},{"key":"153","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.4049\/jimmunol.0801875","article-title":"Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation","volume":"18","author":"Adorini","year":"2009","journal-title":"J Immunol"},{"key":"154","first-page":"96","article-title":"Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia","volume":"6","author":"Steiner","year":"1992","journal-title":"Lab Invest"},{"key":"155","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1084\/jem.161.1.98","article-title":"Massive induction of donor-type class I and class II major histocompatibility complex antigens in rejecting cardiac allografts in the rat","volume":"16","author":"Fabre","year":"1985","journal-title":"J Exp Med"},{"key":"156","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/eurheartj\/8.suppl_J.25","article-title":"Class 1 MHC antigen induction on myocytes in cardiac allograft rejection","volume":"8","author":"Kemnitz","year":"1987","journal-title":"Eur Heart J"},{"key":"157","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0896-8411(90)90140-N","article-title":"Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity?","volume":"3","author":"Bottazzo","year":"1990","journal-title":"J Autoimmun"},{"key":"158","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1161\/01.RES.67.2.360","article-title":"Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with Coxsackievirus B3","volume":"6","author":"Yazaki","year":"1990","journal-title":"Circ Res"},{"key":"159","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1053\/euhj.1998.1085","article-title":"Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury","volume":"1","author":"Rozek","year":"1998","journal-title":"Eur Heart J"},{"key":"160","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.27264","article-title":"Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes","volume":"6","author":"Lundberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"161","first-page":"337","article-title":"Abnormal expression of histocompatibility and mitochondrial antigens by cardiac tissue from patients with myocarditis and dilated cardiomyopathy","volume":"13","author":"Herskowitz","year":"1991","journal-title":"Am J Pathol"},{"key":"162","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/jcp.40.8.879","article-title":"Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man","volume":"4","author":"McGee","year":"1987","journal-title":"J Clin Pathol"},{"key":"163","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1128\/JVI.02415-06","article-title":"The level of viral antigen presented by hepatocytes influences CD8 T-cell function","volume":"8","author":"Bertoletti","year":"2007","journal-title":"J Virol"},{"key":"164","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/jcp.44.2.107","article-title":"Class I and class II major histocompatibility complex antigens on hepatocytes: importance of the method of detection and expression in histologically normal and diseased livers","volume":"4","author":"Vergani","year":"1991","journal-title":"J Clin Pathol"},{"key":"165","first-page":"303","article-title":"Expression of HLA-DR antigen on hepatic vascular endothelial cells in idiopathic portal hypertension","volume":"8","author":"Obata","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"166","first-page":"993","article-title":"HLA-DR expression on the microvasculature of portal tracts in idiopathic portal hypertension","volume":"11","author":"Obata","year":"1991","journal-title":"Immunohistochemical characteristics and relation to portal phlebosclerosis. Arch Pathol Lab Med"},{"key":"167","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pharmtox-010510-100556","article-title":"The expression and function of organic anion transporting polypeptides in normal tissues and in cancer","volume":"5","author":"Hagenbuch","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"168","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1208\/s12248-015-9740-x","article-title":"Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy","volume":"1","author":"Lee","year":"2015","journal-title":"AAPS J"},{"key":"169","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3892\/ijo.2014.2731","article-title":"The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells","volume":"4","author":"Jager","year":"2015","journal-title":"Int J Oncol"},{"key":"170","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.biopha.2011.04.031","article-title":"Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport","volume":"6","author":"J\u00e4ger","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"171","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1124\/dmd.116.071183","article-title":"Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis","volume":"4","author":"Neuhoff","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"172","doi-asserted-by":"publisher","first-page":"13993","DOI":"10.1074\/jbc.271.24.13993","article-title":"Conformation of human leukocyte antigen class II molecules","volume":"27","author":"Ericson","year":"1996","journal-title":"Evidence for superdimers and empty molecules on human antigen presenting cells. J Biol Chem"},{"key":"173","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1089\/cbr.2006.21.645","article-title":"Direct antilymphoma activity of novel, first-generation \u201cantibody mimics\u201d that bind HLA-DR10-positive non-Hodgkin\u2019s lymphoma cells","volume":"2","author":"DeNardo","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"174","first-page":"139","article-title":"Selective high affinity ligands: A new class of targeting agents for cancer imaging and therapy","author":"Baum","year":"2014","journal-title":"Therapeutic Nuclear Medicine, in Series Medical Radiology\/Radiation Oncology"},{"key":"175","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1476-4598-8-25","article-title":"Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells","volume":"8","author":"Denardo","year":"2009","journal-title":"Mol Cancer"},{"key":"176","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics","volume":"34","author":"Lundberg","year":"2015","journal-title":"Tissue-based map of the human proteome. Science"},{"key":"177","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0140-6736(84)91108-5","article-title":"Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis","volume":"2","author":"Bottazzo","year":"1984","journal-title":"Lancet"},{"key":"178","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1084\/jem.159.6.1784","article-title":"Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease","volume":"15","author":"Stingl","year":"1984","journal-title":"J Exp Med"},{"key":"179","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/s0022-5347(17)35762-2","article-title":"HLA expression by benign and malignant prostatic epithelium: augmentation by interferon-gamma","volume":"15","author":"Narayan","year":"1993","journal-title":"J Urol"},{"key":"180","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.4049\/jimmunol.1000971","article-title":"Cutting edge: MHC class II expression by pulmonary nonhematopoietic cells plays a critical role in controlling local inflammatory responses","volume":"18","author":"Krupnick","year":"2010","journal-title":"J Immunol"},{"key":"181","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0016-5085(91)90575-6","article-title":"Expression of class II molecules on intestinal epithelial cells in humans","volume":"10","author":"Piccinini","year":"1991","journal-title":"Differences between normal and inflammatory bowel disease. Gastroenterology"},{"key":"182","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/BF01535942","article-title":"Expression of HLA-DR antigens in inflammatory bowel disease mucosa: Role of intestinal lamina propria mononuclear cell-derived interferon \u03b3","volume":"3","author":"Fiocchi","year":"1988","journal-title":"Dig Dis Sci"},{"key":"183","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00006676-199007000-00007","article-title":"Lymphocyte subsets and HLA-DR expression in normal pancreas and chronic pancreatitis","volume":"5","author":"Martin","year":"1990","journal-title":"Pancreas"},{"key":"184","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/s0735-1097(02)01990-3","article-title":"Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies","volume":"4","author":"Schultheiss","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"185","first-page":"573","article-title":"HLA-DR-positive leucocyte subpopulations in human skin include dendritic cells, macrophages, and CD7-negative T cells","volume":"6","author":"Hart","year":"1988","journal-title":"Immunology"},{"key":"186","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1084\/jem.164.4.1013","article-title":"Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques","volume":"16","author":"Carter","year":"1986","journal-title":"J Exp Med"},{"key":"187","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1365-2133.1986.tb02851.x","article-title":"HLA-DR expression on keratinocytes is a common feature of diseased skin","volume":"11","author":"Fritsch","year":"1986","journal-title":"Br J Dermatol"},{"key":"188","first-page":"1","article-title":"Beta-2-microglobulin and HLA-DR(Ia)-antigens in normal and pathological skin","volume":"9","author":"Tjernlund","year":"1981","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"189","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005072-199003000-00005","article-title":"Multiple sclerosis: a role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study","volume":"4","author":"Raine","year":"1990","journal-title":"J Neuropathol Exp Neurol"},{"key":"190","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/archneur.1991.00530240048017","article-title":"Astrocyte expression of major histocompatibility complex gene products in multiple sclerosis brain tissue obtained by stereotactic biopsy","volume":"4","author":"Estes","year":"1991","journal-title":"Arch Neurol"},{"key":"191","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/ijc.2910410819","article-title":"Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies","volume":"3","author":"Epstein","year":"1988","journal-title":"Int J Cancer Suppl"},{"key":"192","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/1097-0142(19940301)73:5<1425::AID-CNCR2820730517>3.0.CO;2-D","article-title":"Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia","volume":"7","author":"O\u2019Grady","year":"1994","journal-title":"Cancer"},{"key":"193","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1080\/10428190701272272","article-title":"Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines","volume":"4","author":"Denardo","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"194","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00428-004-1143-9","article-title":"Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast","volume":"44","author":"Itoyama","year":"2005","journal-title":"Virchows Arch"},{"key":"195","first-page":"96","article-title":"Medullary breast carcinoma","volume":"3","author":"Kiyamova","year":"2008","journal-title":"Exp Oncol"},{"key":"196","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/1097-0142(194907)2:4<635::AID-CNCR2820020411>3.0.CO;2-Q","article-title":"The relatively favorable prognosis of medullary carcinoma of the breast","volume":"2","author":"Foote","year":"1949","journal-title":"Cancer"},{"key":"197","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4048\/jbc.2013.16.4.417","article-title":"Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma","volume":"1","author":"Nam","year":"2013","journal-title":"J Breast Cancer"},{"key":"198","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1073\/pnas.90.18.8581","article-title":"Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization","volume":"9","author":"Long","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"199","unstructured":"Cancer Facts & Figures 2019, https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2019.html. (Accessed on August 21, 2019)."},{"key":"200","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1158\/1078-0432.CCR-06-0165","article-title":"CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory","volume":"1","author":"Accolla","year":"2006","journal-title":"Clin Cancer Res"},{"key":"201","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.165.10.5451","article-title":"Tumor Cells Present MHC Class II-Restricted Nuclear and Mitochondrial Antigens and Are the Predominant Antigen Presenting Cells","volume":"16","author":"Ostrand-Rosenberg","year":"2000","journal-title":"J Immunol"},{"key":"202","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/10446670310001642410","article-title":"Magnitude of alloresponses to MHC class I\/II expressing human cardiac myocytes is limited by their intrinsic ability to process and present antigenic peptides","volume":"1","author":"Ansari","year":"2003","journal-title":"Clin Dev Immunol"},{"key":"203","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1158\/1078-0432.CCR-12-1182","article-title":"Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients","volume":"1","author":"Wu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"204","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1038\/sj.leu.2402742","article-title":"Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes","volume":"1","author":"Yasukawa","year":"2002","journal-title":"Leukemia"},{"key":"205","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.183.3.1185","article-title":"A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes","volume":"18","author":"Rosenberg","year":"1996","journal-title":"J Exp Med"},{"key":"206","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1126\/science.284.5418.1351","article-title":"Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen","volume":"28","author":"Rosenberg","year":"1999","journal-title":"Science"},{"key":"207","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.7652577","article-title":"A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma","volume":"26","author":"Beach","year":"1995","journal-title":"Science"},{"key":"208","doi-asserted-by":"publisher","first-page":"32676","DOI":"10.1074\/jbc.M604847200","article-title":"Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity","volume":"28","author":"Mamula","year":"2006","journal-title":"J Biol Chem"},{"key":"209","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4049\/jimmunol.167.1.147","article-title":"An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin","volume":"16","author":"Elliott","year":"2001","journal-title":"J Immunol"},{"key":"210","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2002-03-0933","article-title":"Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3","volume":"10","author":"Protti","year":"2003","journal-title":"Blood"},{"key":"211","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.4049\/jimmunol.172.8.5095","article-title":"Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1\/Th2 lymphocytes","volume":"17","author":"Osanto","year":"2004","journal-title":"J Immunol"},{"key":"212","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1349-7006.2011.01986.x","article-title":"Identification of promiscuous HLA-DR-restricted CD4T-cell epitopes on the cancer-testis antigen HCA587","volume":"10","author":"Yin","year":"2011","journal-title":"Cancer Sci"},{"key":"213","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.180.1.35","article-title":"A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas","volume":"18","author":"Boon","year":"1994","journal-title":"J Exp Med"},{"key":"214","first-page":"1343","article-title":"Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes","volume":"15","author":"Robbins","year":"1995","journal-title":"J Immunol"},{"key":"215","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1084\/jem.180.1.347","article-title":"Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes","volume":"18","author":"Rosenberg","year":"1994","journal-title":"J Exp Med"},{"key":"216","first-page":"3961","article-title":"Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated withtumor regression","volume":"15","author":"Rosenberg","year":"1995","journal-title":"J Immunol"},{"key":"217","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1084\/jem.184.6.2207","article-title":"Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes","volume":"18","author":"Rosenberg","year":"1996","journal-title":"J Exp Med"},{"key":"218","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/eji.1830240340","article-title":"Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes","volume":"2","author":"Boon","year":"1994","journal-title":"Eur J Immunol"},{"key":"219","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","article-title":"Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?","volume":"6","author":"Houot","year":"2016","journal-title":"Eur J Cancer"},{"key":"220","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1080\/10428190601078605","article-title":"HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen","volume":"4","author":"Gascoyne","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"221","doi-asserted-by":"publisher","first-page":"e120360","DOI":"10.1172\/jci.insight.120360","article-title":"Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement","volume":"3","author":"Schreeder","year":"2018","journal-title":"JCI Insight"},{"key":"222","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/bjc.1993.290","article-title":"Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis","volume":"6","author":"Hauge","year":"1993","journal-title":"Br J Cancer"},{"key":"223","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/2326-6066.CIR-15-0243","article-title":"Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes","volume":"4","author":"Varley","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"224","first-page":"510","article-title":"An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer","volume":"11","author":"Chen","year":"1994","journal-title":"Surgery"},{"key":"225","first-page":"5382","article-title":"Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes","volume":"15","author":"McCluskey","year":"1994","journal-title":"J Immunol"},{"key":"226","first-page":"180","article-title":"Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy","volume":"1","author":"Xu","year":"2004","journal-title":"Cell Mol Immunol"},{"key":"227","first-page":"398","article-title":"Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence","volume":"7","author":"Grogan","year":"1993","journal-title":"Leukemia"},{"key":"228","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ijc.2910400504","article-title":"B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain","volume":"4","author":"Moller","year":"1987","journal-title":"Int J Cancer"},{"key":"229","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1016\/j.molimm.2008.06.017","article-title":"Characterization of intracellular HLA-DR, DM and DO profile in K562 and HL-60 leukemic cells","volume":"4","author":"Athanassakis","year":"2008","journal-title":"Mol Immunol"},{"key":"230","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0002-9440(10)64181-8","article-title":"Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma","volume":"16","author":"Kitamura","year":"2002","journal-title":"Am J Pathol"},{"key":"231","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JCO.2001.19.3.720","article-title":"Cd4+ T-cell immune response to large B-cell non-Hodgkin\u2019s lymphoma predicts patient outcome","volume":"1","author":"Witzig","year":"2001","journal-title":"J Clin Oncol"},{"key":"232","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ng1060","article-title":"A molecular signature of metastasis in primary solid tumors","volume":"3","author":"Golub","year":"2003","journal-title":"Nat Genet"},{"key":"233","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/blood.V96.10.3569","article-title":"Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites","volume":"9","author":"Kluin","year":"2000","journal-title":"Blood"},{"key":"234","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/1097-0142(19900915)66:6<1154::AID-CNCR2820660613>3.0.CO;2-3","article-title":"An evaluation of the prognostic significance of HLA-DR expression in gastric carcinoma","volume":"6","author":"West","year":"1990","journal-title":"Cancer"},{"key":"235","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1172\/JCI113598","article-title":"HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma","volume":"8","author":"Grogan","year":"1988","journal-title":"J Clin Invest"},{"key":"236","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project","volume":"10","author":"Fuchs","year":"2004","journal-title":"Blood"},{"key":"237","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"34","author":"Averett","year":"2002","journal-title":"N Engl J Med"},{"key":"238","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/10428199109064876","article-title":"Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype","volume":"6","author":"Grogan","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"239","first-page":"5485","article-title":"Overexpression of HLA-DR is associated with prognosis of glioma patients","volume":"8","author":"Zhang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"240","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.3892\/ol.2018.9365","article-title":"Association of CD117 and HLA-DR expression with shorter overall survival and\/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation","volume":"1","author":"Sun","year":"2018","journal-title":"Oncol Lett"},{"key":"241","first-page":"6786","article-title":"Correlation study on CD7, CD34, CD56 and HLA-DR expressions and its prognosis among patients with acute myeloid leukemia","volume":"2","author":"Zhu","year":"2017","journal-title":"Biomed Res"},{"key":"242","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/0952-7915(94)90075-2","article-title":"Tumor immunotherapy: the tumor cell as an antigen-presenting cell","volume":"6","author":"Ostrand-Rosenberg","year":"1994","journal-title":"Curr Opin Immunol"},{"key":"243","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00262-003-0380-0","article-title":"High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell Infiltration, enables murine skin tumours to progress","volume":"5","author":"Halliday","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"244","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.3748\/wjg.v16.i26.3258","article-title":"CD74 is a survival receptor on colon epithelial cells","volume":"1","author":"Shachar","year":"2010","journal-title":"World J Gastroenterol"},{"key":"245","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1073\/pnas.1612195114","article-title":"CD74 is a novel transcription regulator","volume":"11","author":"Lolis","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"246","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"1","author":"Furuta","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"247","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/354392a0","article-title":"Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain","volume":"35","author":"Cresswell","year":"1991","journal-title":"Nature"},{"key":"248","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/cells6010006","article-title":"Invariant Chain Complexes and Clusters as Platforms for MIF Signaling","volume":"6","author":"Lindner","year":"2017","journal-title":"Cells"},{"key":"249","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"21","author":"Nomura","year":"2006","journal-title":"Immunol Rev"},{"key":"250","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1399-0039.2008.01106.x","article-title":"Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands","volume":"7","author":"Ferrone","year":"2008","journal-title":"Tissue Antigens"},{"key":"251","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1038\/onc.2008.267","article-title":"NK cells and cancer immunosurveillance","volume":"2","author":"Steinle","year":"2008","journal-title":"Oncogene"},{"key":"252","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"9","author":"Allison","year":"2006","journal-title":"Adv Immunol"},{"key":"253","first-page":"2833","article-title":"Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells","volume":"16","author":"Kubin","year":"1998","journal-title":"J Immunol"},{"key":"254","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1158\/1078-0432.CCR-06-2547","article-title":"Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients","volume":"1","author":"Durrant","year":"2007","journal-title":"Clin Cancer Res"},{"key":"255","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/bjc.1996.28","article-title":"Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer","volume":"7","author":"Gatter","year":"1996","journal-title":"Br J Cancer"},{"key":"256","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-04-2146","article-title":"Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome","volume":"1","author":"Seliger","year":"2005","journal-title":"Clin Cancer Res"},{"key":"257","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/carcin\/22.10.1615","article-title":"DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas","volume":"2","author":"Yang","year":"2001","journal-title":"Carcinogenesis"},{"key":"258","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/jnci\/87.4.280","article-title":"Molecular characterization of defective antigen processing in human prostate cancer","volume":"8","author":"Simons","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"259","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ijc.25270","article-title":"\u201cHard\u201d and \u201csoft\u201d lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy","volume":"12","author":"Aptsiauri","year":"2010","journal-title":"Int J Cancer"},{"key":"260","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1158\/0008-5472.CAN-06-0029","article-title":"Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2\/neu-specific immunity","volume":"6","author":"Kiessling","year":"2006","journal-title":"Cancer Res"},{"key":"261","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1158\/1078-0432.CCR-19-3417","article-title":"A Humanized Lym-1 CAR with Novel DAP10\/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models","volume":"2","author":"Epstein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"262","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Eliceiri","year":"2012","journal-title":"Nat Methods"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T12:29:31Z","timestamp":1602246571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":262,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["27709","32934776"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27709","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}